Bevacizumab has also been combined with MNRP1685A (242, 323), a mAb against membrane-bound endothelial cell co-receptor neuropilin-1 (NRP1), overexpressed in certain tumor cells, for advanced or metastatic solid tumors (NCT00954642). This evidence concerns the gene NRP1 and neoplasm.